In this study, a transplanted malignant melanoma model demonstrated that a D-peptide-derived p53 activator could restore the p53 signaling pathway by oral administration and specifically degrade MDM2 killer cells in cancer cells [92]. This evidence concerns the gene TP53 and melanoma.